Answers are grounded in this paper and cite their sources.
Versant Ventures and Novartis have launched Borealis Biosciences. Borealis will develop RNA medicines with a focus on kidney disease. The start-up has $150 million in series A funding from Versant and Novartis and a partnership with the latter. Borealis's founders have called it "Chinook Therapeutics 2.0"—a nod to the Versant-founded kidney disease firm Novartis bought in 2023.
No takes yet. Share an insight, caveat, or question.
Rowan Walrath (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: